<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Livanova Plc — News on 6ix</title>
<link>https://6ix.com/company/livanova-plc</link>
<description>Latest news and press releases for Livanova Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 21:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/livanova-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835921078dffbe2df102b7d.webp</url>
<title>Livanova Plc</title>
<link>https://6ix.com/company/livanova-plc</link>
</image>
<item>
<title>Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea</title>
<link>https://6ix.com/company/livanova-plc/news/annals-of-internal-medicine-publishes-12-month-results-from-livanovas-osprey-clinical-study-for-obstructive-sleep-apnea</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/annals-of-internal-medicine-publishes-12-month-results-from-livanovas-osprey-clinical-study-for-obstructive-sleep-apnea</guid>
<pubDate>Mon, 20 Apr 2026 21:05:00 GMT</pubDate>
<description>LONDON, April 20, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company’s OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova’s aura6000™ System for the treatment of moder</description>
</item>
<item>
<title>LivaNova to Announce First-Quarter 2026 Results</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-to-announce-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-to-announce-first-quarter-2026-results</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter</description>
</item>
<item>
<title>LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-receives-us-food-and-drug-administration-premarket-approval-for-aura6000-system-to-treat-moderate-to-severe-obstructive-sleep-apnea</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-receives-us-food-and-drug-administration-premarket-approval-for-aura6000-system-to-treat-moderate-to-severe-obstructive-sleep-apnea</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language –</description>
</item>
<item>
<title>LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-reports-fourth-quarter-and-full-year-2025-results-issues-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-reports-fourth-quarter-and-full-year-2025-results-issues-2026-guidance</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance,</description>
</item>
<item>
<title>Orrum Announces Strategic Partnership with LivaNova to Unite Intelligent Data with Innovative Perfusion Technology</title>
<link>https://6ix.com/company/livanova-plc/news/orrum-announces-strategic-partnership-with-livanova-to-unite-intelligent-data-with-innovative-perfusion-technology</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/orrum-announces-strategic-partnership-with-livanova-to-unite-intelligent-data-with-innovative-perfusion-technology</guid>
<pubDate>Fri, 20 Feb 2026 13:02:00 GMT</pubDate>
<description>Orrum Clinical Analytics today announced a strategic partnership with LivaNova USA Inc. to connect LivaNova's Essenz™ Perfusion System to the analytics and benchmarking capabilities of Orrum's CŌRE Insights™ platform.</description>
</item>
<item>
<title>LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-announce-fourth-quarter-and-full-year-2025-results-2026-01-20</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-announce-fourth-quarter-and-full-year-2025-results-2026-01-20</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter</description>
</item>
<item>
<title>LivaNova to Present at J.P. Morgan Healthcare Conference in January</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-present-jp-morgan-healthcare-conference-january-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-present-jp-morgan-healthcare-conference-january-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th</description>
</item>
<item>
<title>LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-highlight-real-world-evidence-core-vns-study-and-new-health-economics</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-highlight-real-world-evidence-core-vns-study-and-new-health-economics</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy</description>
</item>
<item>
<title>LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-appoints-lucile-blaise-global-head-commercialization-obstructive-sleep-apnea</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-appoints-lucile-blaise-global-head-commercialization-obstructive-sleep-apnea</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global</description>
</item>
<item>
<title>LivaNova to Present at Piper Sandler Healthcare Conference in December</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-present-piper-sandler-healthcare-conference-december-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-present-piper-sandler-healthcare-conference-december-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial</description>
</item>
<item>
<title>LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services</title>
<link>https://6ix.com/company/livanova-plc/news/livanovas-vns-therapy-drug-resistant-epilepsy-procedures-receives-increased-provider</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanovas-vns-therapy-drug-resistant-epilepsy-procedures-receives-increased-provider</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>– New patient implants assigned to New Technology Ambulatory Payment Classification 1580 – End-of-service procedures elevated to Level 5 APC – Effective Jan.</description>
</item>
<item>
<title>LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-delivers-strategic-roadmap-and-long-range-financial-plan-investor-day-2025</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-delivers-strategic-roadmap-and-long-range-financial-plan-investor-day-2025</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Provides 2030 Targets for Revenue and EPS Growth LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today</description>
</item>
<item>
<title>LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-reports-third-quarter-2025-results-raises-2025-guidance-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-reports-third-quarter-2025-results-raises-2025-guidance-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>– Delivered double-digit reported and organic revenue growth and continued operating margin expansion – Raised full-year 2025 revenue, adjusted earnings per</description>
</item>
<item>
<title>LivaNova to Present at Wolfe Research Healthcare Conference in November</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-present-wolfe-research-healthcare-conference-november-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-present-wolfe-research-healthcare-conference-november-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive</description>
</item>
<item>
<title>LivaNova to Announce Third-Quarter 2025 Results</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-announce-third-quarter-2025-results-2025-10-08</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-announce-third-quarter-2025-results-2025-10-08</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter</description>
</item>
<item>
<title>LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-present-scientific-data-international-surgical-sleep-society-2025-annual</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-present-scientific-data-international-surgical-sleep-society-2025-annual</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>Company studies continue to show durability and retention of benefits for patients receiving proximal hypoglossal nerve stimulation for moderate to severe</description>
</item>
<item>
<title>LivaNova Appoints Donald Zurbay as a New Director</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-appoints-donald-zurbay-new-director-2025-09-04</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-appoints-donald-zurbay-new-director-2025-09-04</guid>
<pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the</description>
</item>
<item>
<title>LivaNova to Host Investor Day on November 12, 2025</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-host-investor-day-november-12-2025-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-host-investor-day-november-12-2025-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will host an Investor Day and product</description>
</item>
<item>
<title>LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-present-baird-and-morgan-stanley-global-healthcare-conferences-september</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-present-baird-and-morgan-stanley-global-healthcare-conferences-september</guid>
<pubDate>Fri, 22 Aug 2025 04:00:00 GMT</pubDate>
<description>LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive</description>
</item>
<item>
<title>LivaNova Launches Essenz Perfusion System in China</title>
<link>https://6ix.com/company/livanova-plc/news/livanova-launches-essenz-perfusion-system-china-2025-08-18</link>
<guid isPermaLink="true">https://6ix.com/company/livanova-plc/news/livanova-launches-essenz-perfusion-system-china-2025-08-18</guid>
<pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
<description>Next-generation cardiopulmonary platform surpasses 100,000 patients supported worldwide since 2023 launch LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq:</description>
</item>
</channel>
</rss>